Thanks basparks….this is huge! Even bigger than Alzheimers!
" Field of the Invention
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention Is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30 mg, but further including does of up to about 10Omg per day. Attention Is also directed to A1-41 and A19-144 as similarly useful therapeutics in insomnia, anxiety or agitation. Also presented is a method of moderating systolic blood pressure.
Background of the Invention
Sleep fragmentation, decreased REM and slow-wave sleep (SWS) and circadian rhythm dysfunction are hallmarks of Alzheimer's disease (AD), causing substantial Distress for both patients and their caregivers, and contributing to early
Institutionalization. Sleep disturbances are among the earliest signs of cognitive decline and may accelerate disease progression but there Is a distinct lack of evidence to help guide drug treatment Recent work supports a role for sleep in the development of AD by influencing amyloid beta (?ß) physiology. AB reportedly fluctuates with the sleep-wake cycle with ?ß levels being higher during wakefulness and lower during sleep. Relatedly, sleep deprivation in transgenic mice accelerates AB deposition, whereas improvement of sleep decreases ft. Amyloid deposition further disrupts sleep, potentially through increased astrocytosis.
Insomnia can be grouped into primary and secondary Insomnia, Primary insomnia is a sleep disorder not due to a medical, psychiatric, or environmental cause. It Is described as a complaint of prolonged sleep onset latency, disturbance of sleep maintenance, or the experience of non-refreshing sleep. Conditions that reportedly result in insomnia include depression, pain, benign prostatic hypertrophy, obstructive sleep apnea, restless leg syndrome, and substance misuse. A diagnosis will differentiate between primary insomnia, insomnia as secondary to another condition, and primary Insomnia co-morbid with one or more conditions.
Agitation often accompanies dementia and often precedes the diagnosis of common age-related disorders of cognition such as Alzheimer's disease. More than 80% off people who develop AD eventually become agitated or aggressive.
Occasional anxiety is a normal part of life. Anxiety disorders are characterized by frequent intense, excessive and persistent worry and fear about everyday situations. The disorders often involve repeated episodes of sudden feelings of intense anxiety and fear or terror that reach a peak within minutes (panic attacks)."
Market Data 
Markets 
AI
